Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
Type:
Grant
Filed:
August 9, 2022
Date of Patent:
April 2, 2024
Assignee:
Omeros Corporation
Inventors:
Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
Type:
Application
Filed:
September 6, 2023
Publication date:
March 21, 2024
Applicant:
Omeros Corporation
Inventors:
Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung, Sudheer Babu Vaddela
Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
Type:
Grant
Filed:
April 9, 2021
Date of Patent:
February 13, 2024
Assignees:
Omeros Corporation, University of Leicester
Inventors:
Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
October 2, 2019
Date of Patent:
January 30, 2024
Assignees:
Omeros Corporation, University of Leicester
Inventors:
Hans-Wilhelm Schwaeble, Clark E. Tedford, James B. Parent, Thomas Dudler, Gregory A. Demopulos
Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
Type:
Grant
Filed:
April 27, 2021
Date of Patent:
January 30, 2024
Assignee:
OMEROS CORPORATION
Inventors:
W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
November 7, 2023
Assignee:
Omeros Corporation
Inventors:
Michael Cicirelli, Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Loren Michael Price, Jennifer Tsoung, Sudheer Babu Vaddela
Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
Type:
Application
Filed:
August 9, 2022
Publication date:
September 21, 2023
Applicant:
Omeros Corporation
Inventors:
Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
May 30, 2023
Assignee:
OMEROS CORPORATION
Inventors:
Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung
Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
Type:
Grant
Filed:
August 30, 2017
Date of Patent:
April 18, 2023
Assignee:
OMEROS CORPORATION
Inventors:
Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
March 28, 2023
Assignee:
OMEROS CORPORATION
Inventors:
Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
February 21, 2023
Assignee:
OMEROS CORPORATION
Inventors:
Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
December 13, 2022
Assignees:
OMEROS CORPORATION, UNIVERSITY OF LEICESTER
Inventors:
Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Type:
Grant
Filed:
November 14, 2018
Date of Patent:
October 11, 2022
Assignee:
OMEROS CORPORATION
Inventors:
Gregory A. Demopulos, George A. Gaitanaris, Roberto Ciccocioppo
Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
Type:
Grant
Filed:
July 16, 2020
Date of Patent:
September 27, 2022
Assignee:
OMEROS CORPORATION
Inventors:
Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
Abstract: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR? agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.
Abstract: The present invention provides methods for inhibiting postoperative inflammatory conditions following ophthalmologic surgical procedures by administering intraocularly during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory agent and an alpha-1 adrenergic mydriatic agent, such as a liquid irrigation solution of ketorolac and phenylephrine.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
February 1, 2022
Assignee:
OMEROS CORPORATION
Inventors:
Gregory A. Demopulos, Vincent A. Florio
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Type:
Grant
Filed:
January 15, 2018
Date of Patent:
December 28, 2021
Assignee:
OMEROS CORPORATION
Inventors:
Gregory A. Demopulos, George A. Gaitanaris
Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to antibodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.
Type:
Grant
Filed:
May 31, 2017
Date of Patent:
December 21, 2021
Assignee:
Omeros Corporation
Inventors:
Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
Abstract: In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of CDR-H1, CDR-H2 or CDR-H3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of CDR-L1, CDR-L2 or CDR-L3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.
Type:
Grant
Filed:
March 15, 2017
Date of Patent:
June 29, 2021
Assignee:
Omeros Corporation
Inventors:
W. Jason Cummings, Patrick Gray, Larry Tjoelker, Munehisa Yabuki
Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
Type:
Grant
Filed:
June 23, 2020
Date of Patent:
June 8, 2021
Assignee:
Omeros Corporation
Inventors:
W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki